Toripalimab

PBAC's latest decision on Toripalimab: Recommended with restriction (2025). Considered for First-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine, or second-line treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy.

Eligible population

Adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma with ECOG performance status 0 or 1 (not amenable to salvage surgery or re-irradiation in the first-line setting), with no prior systemic therapy for the first-line indication, or with disease progression on prior platinum-containing chemotherapy for the second-line indication.

Therapy area

Oncology

Line of therapy

First-line | Second-line

Evidence base

RCT

Primary endpoint

PFS

Pivotal trial size

289 patients

Key trials

JUPITER-02, POLARIS-02

Comparator

Cisplatin-gemcitabine (first-line); single-agent chemotherapy (second-line)

Economic model

CUA

ICER note

ICER not stated or published in the public summary document.

Similar precedents

• Nivolumab
  similarity 0.69
• Pembrolizumab
  similarity 0.66
• Nivolumab; ipilimumab
  similarity 0.65
• Crizotinib
  similarity 0.66
• Larotrectinib
  similarity 0.64
• Cabozantinib
  similarity 0.64